This article is more than 5 years old. Information may no longer be current.

Sirna shareholders approve acquisition by Merck

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SAN FRANCISCO — Shareholders of Sirna Therapeutics Inc. have approved the acquisition of the company by Merck & Co. Inc., Sirna announced in a press release.

The acquisition is expected to close as soon as "reasonably practicable," subject to customary closing conditions, the release said.

Sirna is a clinical-stage biotechnology company that develops RNAi-based therapies. In 2005, the company completed a phase 1 clinical trial of Sirna-027 for treating age-related macular degeneration, which it had conducted with Allergan Inc., its strategic partner, and it is moving Sirna-027 forward into phase 2 trials.

The release did not address how the acquisition by Merck will affect that relationship with Allergan.